AARD

Aardvark Therapeutics, Inc.

$1.33

-12.50%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Source: Yahoo Finance
AI summary

Price & performance

1M-71.3%
3M-76.5%
YTD-88.6%
1Y-87.4%
52-week range—
Beta2.07
Full chart and returns against a benchmark

Q-Score

29/ 100

Quality against peers; 50 is the peer median.

Growth—
Risk32
Performance31
Valuation32
Profitability—
Leverage47
Sentiment53
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—
Net income-$57.6M
Net margin—
Historical fundamentals

Valuation

AARDIndustryP/E—85.07P/S—11.67EV/EBITDA—63.25P/B0.396.15PEG—2.86
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report
EPS estimate-$0.75
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate